Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Liwei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5346-5886; OpenAlex author ID A5100406716. Sources: ClinicalTrials.gov.

Their work

Papers
1 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
3
Papers, trials and grants by year

2025: 1 trial · 2026: 1 paper

Papers 1

  1. The bile acid TUDCA promotes chemoresistance and predicts survival through MAPK signaling in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00018-026-06210-4↗

Trials 1

  1. A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China Principal investigator NCT07026123↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yanling Wang · 1 shared paper, 2026 · strength 0.30
  2. Shengbai Xue · 1 shared paper, 2026 · strength 0.30
  3. Jiujie Cui · 1 shared paper, 2026 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.